AbbVie Inc's Fiscal Year is From January To December.
The item "Working-Capital-Turnover" stands at -5.52 as of 09/30/2025.
As of the end of AbbVie Inc's third quarter, the item "Working Capital Turnover" stands at -5.52. This represents a decrease of -12.72 percent compared to it's value at the end of it's second quarter .
Regarding the One-Year-Change of the series, the current value constitutes an increase of 1.68 compared to the value the year prior.
The Serie's long term average value is -14.33. It's latest available value, on 09/30/2025, is 8.81 higher, compared to it's long term average value.
The Serie's change from it's minimum value, on 09/30/2023, to it's latest available value, on 09/30/2025, is +25.49 .
The Serie's change from it's maximum value, on 06/30/2025, to it's latest available value, on 09/30/2025, is -0.6223 .
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Working Capital Turnover | 905,699,262,464.00 |
![]() | Johnson & Johnson - Working Capital Turnover | 486,508,953,600.00 |
![]() | Roche Holding AG - Working Capital Turnover | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Working Capital Turnover | 280,205,508,085.11 |
![]() | Novartis AG - Working Capital Turnover | 255,096,620,580.91 |